EP0146354B2 - Recombinant gamma interferons and pharmaceutical compositions containing them - Google Patents
Recombinant gamma interferons and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- EP0146354B2 EP0146354B2 EP84308710A EP84308710A EP0146354B2 EP 0146354 B2 EP0146354 B2 EP 0146354B2 EP 84308710 A EP84308710 A EP 84308710A EP 84308710 A EP84308710 A EP 84308710A EP 0146354 B2 EP0146354 B2 EP 0146354B2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- gamma interferon
- amino acid
- sequence
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/30—Signal or leader sequence
Definitions
- the present invention relates to the field of recombinant DNA technology, to means and methods utilizing such technology in the preparation of recombinant gamma interferons having enhanced stability, to their production and to the various products of such production and their uses.
- This application is related to GB 2107718.
- Human interferons can be classified in three groups on the basis of different antigenicity and biological and biochemical properties.
- the first group comprises a family of leukocyte interferons which are normally produced mainly by constituent cells of human blood upon viral induction. These have been microbially produced and found to be biologically active (1,2,3). Their biological properties have prompted their use in the clinic as therapeutic agents for the treatment of viral infections and malignant conditions (4).
- human fibroblast interferon normally produced by fibroblasts upon viral induction, which has likewise been microbially produced and found to exhibit a wide range of biological activities (5). Clinical trials also indicate its potential therapeutical value.
- the leukocyte and fibroblast interferons exhibit very clear similarities in their biological properties despite the fact that the degree of homology at the amino acid level is relatively low. Both groups of interferons contain from about 165 to about 166 amino acids and are acid stable proteins.
- Human gamma interferon (also variously referred to as immune interferon, ⁇ -interferon, IIF or IFN- ⁇ ) exhibits the antiviral and anti-proliferative properties characteristic of the interferons but, in contrast to leukocyte and fibroblast interferons, is pH 2 labile. Prior to the production of gamma interferons via recombinant DNA technology, it had been produced mainly upon mitogenic induction of lymphocytes. Human gamma interferon is clearly antigenically distinct from the leukocyte and fibroblast interferons.
- Gray, Goeddel and co-workers were the first to report expression of a recombinant gamma interferon (6), which has proven to exhibit the characteristic properties of human gamma interferon, i.e., anti-viral and anti-proliferative activity coupled with pH 2 lability.
- the recombinant gamma interferon of Gray and Goeddel, as produced in E. coli consisted of 146 amino acids, the N-terminal portion of the molecule commencing with the sequence CYS-TYR-CYS-.
- Alton et a l (17) report on a series of IFN-gammas wherein a single amino acid substitution at position 81 of the Gray et al (6) gamma interferon resulted in an IFN-gamma that retained only 70 percent of the activity (on a relative basis) and wherein an additional deletion of the cys-tyr-cys at positions 1, 2, 3 of this IFN-gamma further reduced relative activity resulting in an IFN-gamma having only 49 percent of the Gray et al (6) gamma interferon.
- the present invention provides gamma interferon polypeptides modified at the N-terminal and/or C-terminal regions with respect to the sequence disclosed in Gray et al, supra, by in one aspect providing a gamma interferon polypeptide consisting of amino acid sequence, extending from the N-terminus : wherein: X is a methionine residue, Y is a glutamine residue and Z consists of n ammo acids in the sequence 127-143 depicted in Fig.
- compositions comprising such gamma interferon polypeptides.
- Z may be part of the sequence starting with Gly 127, or it may be part or all of said sequence in the case where X is a methionine residue.
- the invention also provides corresponding expression vectors capable of producing such interferon polypeptides, and transformants useful in the production through recombinant DNA technology of the interferon polypeptides of the invention.
- Preferred embodiments of the invention exhibit greatly improved stability and activity relative to those previously described in the literature.
- native human gamma interferon i.e., that arising from mitogen induction of human peripheral blood lymphocytes and subsequent purification
- native human gamma interferon is a polypeptide which lacks the CYS-TYR-CYS- N-terminus assigned by Gray et al. to the recombinant gamma interferon whose sequence is depicted in (6).
- Tryptic digests of highly purified native gamma interferon in our hands included sequences whose amino acid composition generally corresponded to that of the N-terminal portion of the Gray et al. recombinant gamma interferon of (6), less CYS-TYR-CYS.
- the CYS-TYR-CYS- containing recombinant gamma interferon earlier reported by Gray and co-workers benefited from formulation with human serum albumin in aid of stabilization.
- the presence of serum albumin in the final lyophilized product requires that certain quality control steps be performed in advance of lyophilization rather than upon finished product.
- the material in lyophilized form has proven to be sufficiently stable without the inclusion of serum albumin.
- the gamma interferons of the invention may be formulated with pharmaceutically acceptable levels of human serum albumin.
- the CYS-TYR-CYS- lacking recombinant human gamma interferons of the invention appear in cytopathic effect inhibition testing to be markedly more active as antiviral agents than their CYS-TYR-CYS- containing analogs.
- the activity is conventionally assayed in microtiter plates by inhibition of the cytopathic effect (CPE) of encephalomyocarditis virus on human lung carcinoma cells A549. See (12).
- the recombinant gamma interferons of the invention include all those comprising amino acids 1 to about 126 of the full sequence provided above.
- Gamma interferons variously truncated at the carboxy terminal end relative to the full sequence continue to exhibit the characteristic properties of human gamma interferon, albeit at diminished levels in some cases, so long as amino acids 1 to about 126 are present.
- experiments with the CYS-TYR-CYS- containing analog reported at (7) showed that extraneous sequences could be substituted for the amino acid sequence following amino acid 132 (by the present numbering system) without loss of activity. See, e.g., (8).
- Recombinant derived gamma interferon in addition to its bearing an initial methionine when produced in hosts where the methionine is not intracellularly cleaved, appears to exhibit a major species having 139 amino acids (based on the numbering system of Figure 1) and a minor species having 143 amino acids.
- the composition of the two species contains greater than about 95 percent, most preferably greater than about 97 percent of the species having 139 amino acids. Trypsin digestion under limiting conditions likewise removes various portions of the sequence downstream from about amino acid 126.
- Recombinant gamma interferon in our hands following such limiting trypsin digestion include species variously extending through amino acids 125, (126 with an initial methionine) 129, 131 and 134.
- Species having at least about 129 amino acids, and especially at least about 131 amino acids, i.e., species having from about 129 to 143 amino acids are essentially functionally fully active.
- recombinant gamma interferon herein we intend a polypeptide (whether or not glycosylated by the cell in which it is produced) expressed in a transformant cell from a replicable expression vehicle arising from recombinant DNA technology, the polypeptide exhibiting in greater or less degree the antiviral and antiproliferative activity in humans and pH 2 labile properties characteristic of native human gamma interferon.
- the recombinant gamma interferons as claimed are believed to form "dimers", defined for the purpose of this disclosure as a combination of two such polypeptides (which polypeptides may have the same or a different number of amino acids).
- the nature of the chemical combining mechanism is not fully understood, but is believed to be other than covalent bonding. This combination into dimers appears to occur spontaneously and is believed to be inevitable in the systems described herein.
- the recombinant gamma interferons of the present invention when administered, they will usually be in the dimerized form.
- purified recombinant gamma interferons will be essentially free of other proteins of human origin, and are so to be distinguished from the native human gamma interferon compositions heretofore available.
- the invention includes recombinant gamma interferon compositions which (prior to formulation) are greater than about 95 percent pure, preferably more than about 98 percent pure, which compositions are for that reason likewise distinct from native gamma interferons heretofore available.
- Embodiments of the invention as claimed in which the N-terminal amino acid residue is methionyl are likewise distinct from gamma interferons produced within the human body, and appear also for that reason to be distinct, beyond their deletion of CYS-TYR-CYS-, from those whose sequence is reported by Gray et al . (6).
- the replicable expression vehicles referred to herein are double- stranded DNA moieties, preferably plasmids, comprising an origin of replication, a promoter or promoter-operator, a sequence encoding a ribosome binding site, a codon for a translation start signal, and in proper reading phase therewith a gene encoding the recombinant gamma interferon of interest, followed by codon(s) for a translation stop.
- the general techniques and lexicography of recombinant DNA technology are well understood to the art-skilled, who are referred in any event to (11) for background information pertinent to the practice of the present invention, mutatis mutandis, in all its embodiments and legally cognizable equivalents.
- Recombinant DNA clones containing gamma interferon cDNA sequences were prepared as described in (6) and in the aforementioned GB 2107718 with messenger RNA from induced human peripheral blood lymphocytes.
- the DNA sequence of clone p67 is shown in Figure 1.
- a 5' untranslated region is followed by 69 nucleotides encoding a precursor or signal peptide of 23 amino acids, 429 nucleotides coding for a mature interferon polypeptide of 143 amino acids, and 587 nucleotides of 3' untranslated sequence.
- An Avall restriction site located at codon 2 of the presumed mature coding sequence was utilized to remove the signal peptide coding region.
- Two synthetic deoxyoligonucleotides were designed which restore the codons for amino acids 1 and 2, incorporate an ATG translational initiation codon, and create an XBaI cohesive terminus. These two oligomers were ligated to the remainder of the cDNA insert to construct a 1063 base-pair synthetic-natural hybrid gene coding for a polypeptide of 144 amino acids and bounded by XBaI and PstI sites. This gene was inserted into the plasmid pLeIF A25 (10) between the XBaI and PstI sites to give the expression plasmid p ⁇ -CYC5.
- E. col strain W3110 (F -, ⁇ -, protrophic) was transformed with this plasmid to give the host-vector combination E . coli W#110/p ⁇ -CYC5.
- Confluent monolayers of COS-7 cells in 60 mm petri dishes were transfected in duplicate with DNA using the modified DEAE-dextran procedure. Three days after DNA addition, the media was removed. Each set of plates received 2 mls DMEM supplemented with either 100 ⁇ Ci S 35 -methionine or S 35 -cysteine. After 16 hours incubation in the presence of the radiolabeled amino acid, the media was removed and 500 ⁇ l immunoprecipitated using an anti-gamma-interferon monoclonal antibody or an anti-HBsAg monoclonal antibody as the first antibody and a rabbit anti-mouse IgG antibody (Cappell Inc.) as the second antibody.
- Plasmids used in this study were pSVgamma69 (11); pDL RI (19), a hepatitis B virus surface antigen expression vector upon which pSVgamma69 was based; and pDL Rlgamma Sau, a polycistronic plasmid containing the 830 bp SAU3a fragment of pSVgamma69 (11) spanning the entire gamma-interferon encoding sequences inserted into the EcoRI site of pDL RI. The latter plasmid produces a transcript containing both the gamma-interferon and the HBsAg coding regions.
- the production of recombinant Human Interferon - Gamma (rIFN- ⁇ ) using E . coli W3110/p ⁇ - CYC5 is carried out in batches ranging in volume from 10 to 1000 liters. After fermentation, the interferon containg E . coli cells are recovered from the broth for isolation and purification of rIFN- ⁇ . The following is a description of the fermentation and cell recovery processes.
- a stock culture is prepared in sterile baffled culture flasks containing 150 to 500 mL of a sterile medium having the following composition.
- the inoculum is prepared in the medium previously described (L.B. Broth) in either shaker flasks or small fermenters. After incubation at about 37°C for approximately 8 hours, the inoculum is transferred to a fermenter. The volume of the inoculum is between 2 to 10 percent of the volume of the fermentation.
- Recombinant Interferon - Gamma production is carried out in fermenters with working volume of about 10 to 1000 liters.
- the fermentation medium is composed of: Per liter Glucose 50-100 g Ammonium Sulfate 4.0-8.0 g Potassium Phosphate, Monobasic 3.0-5.0 g Potassium Phosphate, Dibasic 5.0-8.0 g Magnesium Sulfate, Heptahydrate 0.5-5.1 g Sodium Citrate, Dihydrate 0.5-2.0 g UCON LB-625 0.5-2.0 mL Ferric Chloride, Hexahydrate 0.005-0.15 g Zinc Sulfate, Heptahydrate 0.001-0.15 g Cobalt Chloride, Hexahydrate 0.001-0.005 g Sodium Molybdate, Dihydrate 0.001-0.005 g Cupric Sulfate, Pentahydrate 0.001-0.005 g Boric Acid 0.001-0.005 g Manganese Sulfate, Monohydrate
- Ingredients in the medium are sterilized by heat treatment or filtration prior to use in fermentation.
- the fermentation is carried out at 25-40°C Other operating conditions are as follows: Agitation (rpm) 100-1000 Aeration (wm) 0.5-1.5 (Supplemented with oxygen when necessary) pH 6.5-7.5 (Controlled by the addition of ammonium hydroxide)
- E . coli cells are suspended in a medium which contains salts and an appropriate buffer in the pH range of 6 to 9, preferably about 9.
- Recombinant gamma interferon is extracted by homogenization of the cell suspension in a high pressure colloid mill such as a Gaulin mill.
- Sufficient polyethyleneimine is added to the solution to produce a 0.1 to 1% W/V solution.
- the supernatant contains gamma interferon.
- the supernatant from part (a) is adsorbed to a silica based adsorbant which is washed to remove impurities with appropriate salt solutions in the pH range of 6 to 9.
- Recombinant gamma interferon is eluted using a solution containing 0.5 - 1.0 M tetramethyl ammonium chloride. All operations in this step are performed in the pH range of 7 to 9.
- the eluent from part (b) is dialysed and adsorbed to an anion exchange chromatography medium which is then washed to remove impurities. Recombinant gamma interferon is eluted with a gradient of increasing salt.
- Typical anion exchange resins applicable for this step include carboxymethyl cellulose and sulphoethyl cellulose. All operations are performed in the pH range of between 7 and 9.
- the eluent from part (c) is adsorbed to a medium of calcium phosphate which is then washed to remove impurities.
- the recombinant gamma interferon is eluted by increasing the salt concentration in a gradient of increasing phosphate concentration. All operations in this step are performed in the pH range of between 7 and 9.
- the eluent from part (d) is dialysed and adsorbed to an anion exchange chromatography medium which is then washed to remove impurities.
- the recombinant gamma interferon is eluted from the anion exchange medium with a gradient of increasing salt concentration.
- Typical anion exchange chromatography media are carboxymethyl cellulose and sulphoethyl cellulose. All operations in this step are performed in the pH range of between 7 and 9.
- the eluent from part (e) is applied to a gel permeation medium and the column is developed with a salt containing medium.
- the appropriate recombinant gamma interferon containing fractions are pooled to produce the bulk drug substance. All operations in this step are performed in the pH range of between 7 and 9.
- Recombinant gamma interferon made in accordance with the foregoing is preferably formulated for parenteral administration according to the following Table.
- QUANTITY PER VIAL Ingredient 0.5 mg vial 2.0 mg vial Recombinant Human Interferon - Gamma 0.5 2.0 Mannitol 100 80 Succinic Acid Disodium Hexahydrate 12.4 9.9 Glycine 5.6 4.5 Sodium Chloride 4.4 3.5 Polysorbate 20 0.8 0.6 Succinic Acid 0.5 0.4
- interferons of the invention may be employed in medically appropriate dosage ranges, e.g., 1.0 mg/M 2 of body surface area.
- r-HulFN-gamma recombinant gamma interferon (r-HulFN-gamma) (6.5 mg), prepared as described herein, was desalted over a small Sephadex G-25 molecular sieving column (PD-10, Pharmacia) into 0.10 M Ammonium Bicarbonate buffer, pH 8.5 to a final protein concentration of 2.1 mg/ml.
- a dilute trypsin solution (Worthington TPCK trypsin, 10 ⁇ g/ml in 0.001 M HCl, 16 ⁇ l) was added to 1.9 ml (4.0 mg) of the r-HulFN-gamma solution, mixed and incubated at room temperature (trypsin:protein:1:25,000).
- Protein peaks as determined by absorbance at 214 nm and 280 nm were preparatively collected and stored covered at 4°C until analyzed. Typical analyses for selected peaks included:
- samples are taken to dryness by rotary evaporation, resuspended in 0.5 ml of water and redried. Prior to fractionation by HPLC, samples were redissolved in 50% formic acid to a protein concentration of approximately 1 mg/ml.
- gamma interferons of any length within the range 126aa-143aa (excluding N-terminal methionine) will be expressed from appropriately tailored genes.
- the gene depicted in Figure 1 contains a Fnu4H restriction site at Following restriction with Fnu4H, synthetic oligonucleotides encoding any desired sequence followed by a "stop" codon and a linker compatible with an available restiction site in the expression plasmid may be ligated to the fore part of the gamma interferon gene.
- the sequence wherein X encodes one or more amino acids may be ligated into the E . coli expression vehicle exemplified above following digestion of the plasmid with Fnu4H and BgIII, a stop codon resulting from ligation thusly
- the specific antiviral activity of recombinant human IFN-gamma is approximately three times higher than the activity of the modified rIFN-gamma molecule with three additional amino acids (cys-tyr-cys) at the N-terminus.
- test cells suspended in the culture medium were seeded into plastic tissue culture plates at a concentration of 5 ⁇ 10 3 cells/0.5 ml/well.
- Various amounts of interferon dissolved in the corresponding culture medium were added subsequently (day 0). Cultivation was carried out at 37°C in a humidified atmosphere of 5 percent CO 2 and 95 percent air.
- the culture media were removed and the cells in suspension culture were directly suspended in Isoton II (Coulter Electronics Inc.) for cell counting in a Coulter counter.
- the cells forming a sheet in plastic vessels were pre-treated with 0.05 percent trypsin-0.02 percent EDTA to prepared single cell suspension in Isoton II (Coulter Electronics Inc.).
- Antiproliferative activity of interferon was expressed as the antiviral units required to produce 50 percent reduction of cell number (IC 50 , IU/ml) compared to the control culture (without interferon).
- the antiproliferation activity of rIFN-gamma varied markedly depending on the human cell species.
- KATO-III siglet-ring cell carcinoma of the stomach, was highly sensitive, the cell line showing the IC 50 of 1.2 IU/ml, while Daudi cells, Burkitt's lymphoma, which were highly sensitive to type II interferon (HulFN-alpha, HulFN-beta), were insensitive to type II interferon including rIFN-gamma.
- Lung adenocarcinoma (PC-8, PC-12) was insensitive to all interferon species tested.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56200983A | 1983-12-16 | 1983-12-16 | |
US584217 | 1984-02-27 | ||
US06/584,217 US4855238A (en) | 1983-12-16 | 1984-02-27 | Recombinant gamma interferons having enhanced stability and methods therefor |
US562009 | 1984-02-27 |
Publications (4)
Publication Number | Publication Date |
---|---|
EP0146354A2 EP0146354A2 (en) | 1985-06-26 |
EP0146354A3 EP0146354A3 (en) | 1986-03-19 |
EP0146354B1 EP0146354B1 (en) | 1996-03-13 |
EP0146354B2 true EP0146354B2 (en) | 2001-10-24 |
Family
ID=27072811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84308710A Expired - Lifetime EP0146354B2 (en) | 1983-12-16 | 1984-12-14 | Recombinant gamma interferons and pharmaceutical compositions containing them |
Country Status (23)
Country | Link |
---|---|
US (4) | US4855238A (lv) |
EP (1) | EP0146354B2 (lv) |
JP (6) | JPH0789935B2 (lv) |
KR (1) | KR940008978B1 (lv) |
AT (1) | ATE135405T1 (lv) |
AU (1) | AU597872B2 (lv) |
CA (1) | CA1341573C (lv) |
CY (1) | CY1945A (lv) |
DE (1) | DE3486424T3 (lv) |
DK (1) | DK166832B1 (lv) |
ES (1) | ES8801553A1 (lv) |
FI (1) | FI91884C (lv) |
GR (1) | GR82468B (lv) |
HK (1) | HK175996A (lv) |
HU (1) | HU202278B (lv) |
IE (1) | IE72494B1 (lv) |
IL (1) | IL73803A (lv) |
LV (1) | LV11633B (lv) |
MY (1) | MY102899A (lv) |
NO (1) | NO178789C (lv) |
OA (1) | OA07902A (lv) |
PH (1) | PH24790A (lv) |
PT (1) | PT79691A (lv) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785599B2 (en) | 2000-04-12 | 2010-08-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
GB8406910D0 (en) * | 1984-03-16 | 1984-04-18 | Biogen Nv | Gamma interferon |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
ZA846554B (en) * | 1983-09-20 | 1985-04-24 | Hoffmann La Roche | Immune interferon and method for its purification |
MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
JPS60172999A (ja) * | 1983-12-20 | 1985-09-06 | Suntory Ltd | 新規な塩基性ポリペプチドおよびその製造法 |
US4758656A (en) * | 1983-12-26 | 1988-07-19 | Kyowa Hakko Kogyo Co., Ltd. | Novel human interferon-gamma polypeptide derivative |
DE3582542D1 (de) * | 1984-03-16 | 1991-05-23 | Biogen Nv | Verfahren zur expressionsverbesserung und mittel hierfuer. |
DE3414831A1 (de) * | 1984-04-19 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Herstellung von polypeptiden mit human-gammainterferon-aktivitaet |
IL75302A0 (en) * | 1984-06-06 | 1985-09-29 | Takeda Chemical Industries Ltd | Novel polypeptide and production thereof |
CA1302320C (en) * | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
JPS61108397A (ja) * | 1984-10-31 | 1986-05-27 | Green Cross Corp:The | インタ−フエロン−γ蛋白質の製造法 |
JPS6156195A (ja) * | 1985-03-01 | 1986-03-20 | Asahi Chem Ind Co Ltd | 新規生理活性ペプチド |
US4873312A (en) * | 1985-04-25 | 1989-10-10 | Amgen | Method for purifying interferon and composition of matter produced thereby |
IE58766B1 (en) * | 1985-04-30 | 1993-11-03 | Takeda Chemical Industries Ltd | Production of protein |
DE3532134A1 (de) * | 1985-09-10 | 1987-03-12 | Basf Ag | Verfahren zur herstellung von proteinen bestimmter n-terminaler struktur mit hilfe von prokaryonten |
DE3536939A1 (de) * | 1985-10-17 | 1987-04-23 | Hoechst Ag | Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten |
EP0275300B1 (en) * | 1986-08-01 | 1996-01-03 | Commonwealth Scientific And Industrial Research Organisation | Recombinant vaccine |
GB8619725D0 (en) * | 1986-08-13 | 1986-09-24 | Hoffmann La Roche | Homogenous interferon fragments |
US5157004A (en) * | 1986-12-27 | 1992-10-20 | Takeda Chemical Industries, Ltd. | Polypeptides and production thereof |
JP2653061B2 (ja) * | 1986-12-27 | 1997-09-10 | 武田薬品工業株式会社 | 新規ポリペプチドおよびその製造法 |
DE3730331A1 (de) * | 1987-09-10 | 1989-03-30 | Basf Ag | Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus |
AT393690B (de) * | 1987-10-08 | 1991-11-25 | Hoffmann La Roche | Homogene, rekombinante immun-interferonfragmente |
US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
DE68929273T2 (de) * | 1988-08-24 | 2001-07-05 | American Cyanamid Co | Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung |
US5198212A (en) * | 1988-10-31 | 1993-03-30 | University Of Lousville Research Foundation Incorporated | Method and compositions for treatment of trauma-associated sepsis with gamma interferon |
US6068994A (en) * | 1989-08-07 | 2000-05-30 | Chiron Corporation | Ubiquitin expression system |
BG52073B2 (en) * | 1990-01-24 | 1996-04-30 | Inst Molekuljarna Biolog | Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine |
ATE112686T1 (de) * | 1990-08-31 | 1994-10-15 | Schering Corp | Verwendungsmethoden von humanem gammainterferon 4-134. |
DE4036856C1 (lv) * | 1990-11-19 | 1992-05-27 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De | |
US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5328989A (en) * | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
CA2165666A1 (en) * | 1993-07-01 | 1995-01-12 | Hugh George | Culture medium for recombinant yeasts |
TW249202B (lv) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US6187304B1 (en) | 1998-04-02 | 2001-02-13 | Genentech, Inc. | Effects of IFN-γ on cardiac hypertrophy |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
RU2140285C1 (ru) | 1999-01-25 | 1999-10-27 | Гапонюк Петр Яковлевич | Противовирусное средство - капли в нос "гриппферон" |
JP2003507006A (ja) * | 1999-05-20 | 2003-02-25 | サイオス,インコーポレーテッド | 血管内皮増殖因子改変体 |
EP1183357A2 (en) * | 1999-05-20 | 2002-03-06 | Scios Inc. | Vascular endothelial growth factor dimers |
CN1309423C (zh) | 1999-11-12 | 2007-04-11 | 马克西根控股公司 | 干扰素γ偶联物 |
CA2390292A1 (en) * | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
DE60129432T2 (de) * | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
KR20040007413A (ko) * | 2000-11-03 | 2004-01-24 | 바이오메디신즈 인코포레이티드 | 단기 및 장기 약물 약량측정 방법 |
DE60239522D1 (de) * | 2001-01-09 | 2011-05-05 | Baylor Res Inst Dallas | Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays |
US7038015B2 (en) * | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
US6958388B2 (en) | 2001-04-06 | 2005-10-25 | Maxygen, Aps | Interferon gamma polypeptide variants |
IL161630A0 (en) * | 2001-11-06 | 2004-09-27 | Applied Research Systems | Methods of treating endometreosis |
EP1450839A4 (en) * | 2001-11-06 | 2009-06-24 | Serono Lab | METHOD OF TREATING BREAST CANCER THAT MEETS OESTROGENES |
US20030143197A1 (en) * | 2001-11-09 | 2003-07-31 | Moran S. Mark | Method for treating diseases with omega interferon |
EP1461067A1 (en) * | 2001-12-07 | 2004-09-29 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
US7524931B2 (en) * | 2002-07-03 | 2009-04-28 | Maxygen Holdings Ltd. | Full-length interferon gamma polypeptide variants |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US20070092488A1 (en) * | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
TWI375679B (en) | 2003-10-14 | 2012-11-01 | Hoffmann La Roche | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
KR20070007086A (ko) | 2004-02-02 | 2007-01-12 | 암브룩스, 인코포레이티드 | 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도 |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2006141263A (ja) * | 2004-11-18 | 2006-06-08 | Kyoto Univ | (r)−ヒドロキシニトリルリアーゼの製造方法 |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
KR20080019606A (ko) * | 2005-05-04 | 2008-03-04 | 나우틸루스 바이오텍 | 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법 |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
BRPI0716959A2 (pt) | 2006-09-26 | 2013-10-29 | Infectious Disease Res Inst | Composição de vacina contendo adjuvante sintético |
US8617531B2 (en) * | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
CN105688191A (zh) | 2007-04-23 | 2016-06-22 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
US8243103B2 (en) * | 2009-05-29 | 2012-08-14 | Exelis, Inc. | Laser aiming spot distinguishing methods and apparatus |
EP3124491B1 (en) | 2009-06-05 | 2019-10-30 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them |
MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
RU2575598C9 (ru) * | 2010-02-01 | 2016-04-27 | Дигна Байотек, С.Л. | Способ получения белка альфа5-интерферона |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2013024158A1 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
WO2013024156A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
WO2014033266A1 (en) | 2012-08-31 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection |
MX370573B (es) | 2013-04-18 | 2019-12-17 | Immune Design Corp | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
JP7195148B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Tlrアゴニストを含有する製剤及び使用方法 |
MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
WO2017210364A1 (en) | 2016-06-01 | 2017-12-07 | Infectious Disease Research Institute | Nanoalum particles containing a sizing agent |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
US11672877B2 (en) | 2017-08-23 | 2023-06-13 | Wayne State University | In vivo immunoimaging of interferon-gamma |
WO2019051149A1 (en) | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE |
BR112022018615A2 (pt) | 2020-03-19 | 2022-12-20 | Trizell Ltd | Sistema de armazenamento de vírus sensível à temperatura |
KR20230012471A (ko) | 2020-03-30 | 2023-01-26 | 트리젤 엘티디. | 암 치료용 조성물 및 방법 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
NL7404590A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het reactiveren van interferon. |
US4332892A (en) * | 1979-01-15 | 1982-06-01 | President And Fellows Of Harvard College | Protein synthesis |
JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
AU538665B2 (en) * | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
GB2068970B (en) * | 1980-02-06 | 1983-06-22 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4460685A (en) * | 1980-05-29 | 1984-07-17 | New York University | Method of enhancing the production of human γ Interferon |
US4341761A (en) * | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
US4311639A (en) * | 1980-07-25 | 1982-01-19 | E. I. Du Pont De Nemours And Company | Immunogenic interferon peptides |
FI64813C (fi) * | 1980-12-31 | 1984-01-10 | Ilkka Antero Palva | Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer |
IL65475A0 (en) * | 1981-04-17 | 1982-07-30 | Meloy Lab | Production of immune interferon and its mrna |
US4382027A (en) * | 1981-08-18 | 1983-05-03 | Meloy Laboratories, Inc. | Purification of human immune interferon |
US4404188A (en) * | 1981-07-29 | 1983-09-13 | Massachusetts General Hospital | Purified Mullerian Inhibiting Substance and method of purification |
US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5096705A (en) * | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
US4361509A (en) * | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
US4388234A (en) * | 1981-12-28 | 1983-06-14 | Hoffmann-La Roche Inc. | Peptide isolation |
ZA831094B (en) * | 1982-02-22 | 1983-11-30 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides |
US5004689A (en) * | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
ZA83768B (en) * | 1982-03-01 | 1983-10-26 | Hoffmann La Roche | Homogeneous human immune interferon and process therefor |
IL68100A0 (en) * | 1982-03-24 | 1983-06-15 | Takeda Chemical Industries Ltd | Novel dna and use thereof |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
JPH0787797B2 (ja) * | 1982-05-20 | 1995-09-27 | サントリー株式会社 | ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法 |
US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
IL69851A0 (en) * | 1982-09-30 | 1983-12-30 | Japan Found Cancer | Novel dna and recombinant plasmid containing the same |
WO1984002129A1 (en) * | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
US4485017A (en) * | 1982-12-22 | 1984-11-27 | Cetus Corporation | Isolation of human interferon by immunosorbent and high performance liquid chromatography |
JPH0740925B2 (ja) * | 1983-03-14 | 1995-05-10 | 協和醗酵工業株式会社 | 新規ヒトインタ−フエロン−γポリペプチド |
JPS59169494A (ja) * | 1983-03-17 | 1984-09-25 | Takeda Chem Ind Ltd | 新規組み換えdnaおよびその用途 |
US4599306A (en) * | 1983-04-15 | 1986-07-08 | Amgen | Monoclonal antibodies which specifically bind to human immune interferon |
NZ208309A (en) * | 1983-06-01 | 1988-04-29 | Hoffmann La Roche | Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced |
IL72773A0 (en) * | 1983-08-29 | 1984-11-30 | Meloy Lab | Production of immune interferon and its mrna |
US4604284A (en) * | 1983-09-20 | 1986-08-05 | Hoffmann-La Roche Inc. | Homogeneous immune interferon fragment |
US4476049A (en) * | 1983-09-20 | 1984-10-09 | Hoffmann-La Roche Inc. | Method for the extraction of immune interferon |
US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
JPS6079000A (ja) * | 1983-10-04 | 1985-05-04 | Takeda Chem Ind Ltd | ヒトγ型インタ−フエロン単量体の製造法 |
JPH0788398B2 (ja) * | 1983-10-17 | 1995-09-27 | サントリー株式会社 | 新規生理活性ポリペプチドおよびその製造法 |
JPS60118196A (ja) * | 1983-11-30 | 1985-06-25 | Takeda Chem Ind Ltd | インタ−フェロンの製造法 |
FR2556365B1 (fr) * | 1983-12-09 | 1987-07-31 | Transgene Sa | Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g |
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
IL75302A0 (en) * | 1984-06-06 | 1985-09-29 | Takeda Chemical Industries Ltd | Novel polypeptide and production thereof |
JP2653061B2 (ja) | 1986-12-27 | 1997-09-10 | 武田薬品工業株式会社 | 新規ポリペプチドおよびその製造法 |
-
1984
- 1984-02-27 US US06/584,217 patent/US4855238A/en not_active Expired - Lifetime
- 1984-12-11 IL IL73803A patent/IL73803A/xx not_active IP Right Cessation
- 1984-12-12 PH PH31568A patent/PH24790A/en unknown
- 1984-12-13 CA CA000470076A patent/CA1341573C/en not_active Expired - Fee Related
- 1984-12-13 AU AU36635/84A patent/AU597872B2/en not_active Expired
- 1984-12-13 FI FI844934A patent/FI91884C/fi active IP Right Grant
- 1984-12-13 IE IE320384A patent/IE72494B1/en not_active IP Right Cessation
- 1984-12-13 KR KR1019840007908A patent/KR940008978B1/ko not_active IP Right Cessation
- 1984-12-13 JP JP59263699A patent/JPH0789935B2/ja not_active Expired - Lifetime
- 1984-12-14 DK DK600984A patent/DK166832B1/da not_active IP Right Cessation
- 1984-12-14 AT AT84308710T patent/ATE135405T1/de not_active IP Right Cessation
- 1984-12-14 EP EP84308710A patent/EP0146354B2/en not_active Expired - Lifetime
- 1984-12-14 CY CY194584A patent/CY1945A/xx unknown
- 1984-12-14 PT PT79691A patent/PT79691A/pt unknown
- 1984-12-14 GR GR82468A patent/GR82468B/el unknown
- 1984-12-14 NO NO845042A patent/NO178789C/no not_active IP Right Cessation
- 1984-12-14 DE DE3486424T patent/DE3486424T3/de not_active Expired - Lifetime
- 1984-12-14 ES ES538620A patent/ES8801553A1/es not_active Expired
- 1984-12-14 HU HU844669A patent/HU202278B/hu unknown
- 1984-12-17 OA OA58479A patent/OA07902A/xx unknown
-
1987
- 1987-09-21 MY MYPI87001799A patent/MY102899A/en unknown
-
1990
- 1990-09-10 JP JP2239776A patent/JPH0794477B2/ja not_active Expired - Lifetime
-
1994
- 1994-03-24 US US08/221,542 patent/US5595888A/en not_active Expired - Fee Related
- 1994-07-13 JP JP6161166A patent/JP2580491B2/ja not_active Expired - Lifetime
- 1994-09-23 US US08/311,765 patent/US5574137A/en not_active Expired - Lifetime
-
1995
- 1995-05-10 JP JP7111822A patent/JP2545206B2/ja not_active Expired - Lifetime
- 1995-06-02 US US08/460,539 patent/US6497871B1/en not_active Expired - Lifetime
-
1996
- 1996-03-12 JP JP8054569A patent/JP2719128B2/ja not_active Expired - Lifetime
- 1996-07-17 LV LVP-96-250A patent/LV11633B/en unknown
- 1996-09-19 HK HK175996A patent/HK175996A/xx not_active IP Right Cessation
-
1997
- 1997-08-04 JP JP9208916A patent/JP2886145B2/ja not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785599B2 (en) | 2000-04-12 | 2010-08-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8071539B2 (en) | 2001-12-21 | 2011-12-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8252739B2 (en) | 2001-12-21 | 2012-08-28 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8513189B2 (en) | 2001-12-21 | 2013-08-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0146354B2 (en) | Recombinant gamma interferons and pharmaceutical compositions containing them | |
US5690925A (en) | Recombinant gamma interferons having enhanced stability and methods therefor | |
EP0225579B1 (en) | Covalently linked polypeptide cell modulators | |
Rinderknecht et al. | Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. | |
EP0826049A1 (en) | Human interferon tau compositions and methods of use | |
Pontzer et al. | Structure/function studies with interferon tau: evidence for multiple active sites | |
US4855409A (en) | Novel polypeptides and method of producing same | |
US4980455A (en) | Novel polypeptides and production thereof | |
Kung et al. | [29] Purification of recombinant human immune interferon | |
US7052867B2 (en) | Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same | |
IE61444B1 (en) | Process for preparing and purifying interferon | |
Sano et al. | Constitutive long-term production and characterization of recombinant human interferon-gammas from two different mammalian cells | |
Hayes | Differences between human α (leukocyte) and β (fibroblast) interferons | |
MIYATA et al. | Pruification of Natural Human Interferon-Gamma by Antibody Affinity Chromatography: Analysis of Constituent Protein Species in the Dimers | |
JPS615096A (ja) | 新規ポリペプチドおよびその製造法 | |
Le et al. | Purification and properties of a novel recombinant human hybrid interferon, σ-4 α2/α1 | |
Stebbing | Interferon hybrids: prospects for therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19860212 |
|
17Q | First examination report despatched |
Effective date: 19880711 |
|
EL | Fr: translation of claims filed | ||
111L | Licence recorded |
Free format text: 0100 BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 135405 Country of ref document: AT Date of ref document: 19960315 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3486424 Country of ref document: DE Date of ref document: 19960418 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
MEDD | It: supplementary protection certificate for pharmaceutical products: granted |
Free format text: CCP 542, 19960911; GENENTECH INC. |
|
PLAV | Examination of admissibility of opposition |
Free format text: ORIGINAL CODE: EPIDOS OPEX |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
26 | Opposition filed |
Opponent name: GENENTECH, INC. Effective date: 19961210 |
|
R26 | Opposition filed (corrected) |
Opponent name: AMGEN INC. Effective date: 19961210 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: GENENTECH, INC. |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: AMGEN INC. |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLAW | Interlocutory decision in opposition |
Free format text: ORIGINAL CODE: EPIDOS IDOP |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
APAE | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOS REFNO |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
PLAW | Interlocutory decision in opposition |
Free format text: ORIGINAL CODE: EPIDOS IDOP |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20011024 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
NLR2 | Nl: decision of opposition | ||
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
ET3 | Fr: translation filed ** decision concerning opposition | ||
NLR3 | Nl: receipt of modified translations in the netherlands language after an opposition procedure | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20031204 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20031205 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031210 Year of fee payment: 20 Ref country code: FR Payment date: 20031210 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20031211 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20031216 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20031223 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20031229 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20040212 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041213 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041213 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041213 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041214 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041214 |
|
BE20 | Be: patent expired |
Owner name: *GENENTECH INC. Effective date: 20041214 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
EUG | Se: european patent has lapsed | ||
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20041214 |
|
EUG | Se: european patent has lapsed | ||
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AEN Free format text: MAINTIEN DU BREVET DONT L'ETENDUE A ETE MODIFIEE |